Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 12

1.

Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):57-65. doi: 10.1016/j.drugalcdep.2011.10.018. Epub 2011 Nov 12.

2.

Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Syed YY, Keating GM.

CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review.

PMID:
24018540
3.

Intramuscular extended-release naltrexone: current evidence.

Gastfriend DR.

Ann N Y Acad Sci. 2011 Jan;1216:144-66. doi: 10.1111/j.1749-6632.2010.05900.x. Review. Erratum in: Ann N Y Acad Sci. 2011 Apr;1224(1):207.

PMID:
21272018
4.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
5.

Vivitrex (Alkermes/Cephalon).

Heading CE.

Curr Opin Investig Drugs. 2006 Jan;7(1):81-8. Review.

PMID:
16425675
6.

Sustained-release naltrexone for opioid dependence.

Lobmaier P, Kornør H, Kunøe N, Bjørndal A.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006140. doi: 10.1002/14651858.CD006140.pub2. Review.

PMID:
18425938
7.

Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.

Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D.

J Control Release. 2014 Jun 10;183:154-66. doi: 10.1016/j.jconrel.2014.03.046. Epub 2014 Apr 2. Review.

PMID:
24704710
8.

Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.

Kunøe N, Lobmaier P, Ngo H, Hulse G.

Br J Clin Pharmacol. 2014 Feb;77(2):264-71. doi: 10.1111/bcp.12011. Review.

9.

Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G.

Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Epub 2012 Mar 12. Review.

10.

Morphine/naltrexone.

Duggan ST, Scott LJ.

CNS Drugs. 2010 Jun;24(6):527-38. doi: 10.2165/11204620-000000000-00000. Review.

PMID:
20443648
11.

[A review of naltrexone maintenance programs: effectiveness, predictors and profile].

Madoz-Gúrpide A, Ochoa E, Baca-García E.

Med Clin (Barc). 2002 Sep 21;119(9):351-5. Review. Spanish. No abstract available.

PMID:
12356367
12.

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

Younger J, Parkitny L, McLain D.

Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk